Cytori Therapeutics Net income (Q1, 2018)-4.4 M

Cytori Therapeutics EBIT (Q1, 2018)-4.4 M

Cytori Therapeutics Cash, 31-Mar-20185.9 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Revenue | 7.1 m | 5 m | 4.8 m | 4.7 m | |

| (30%) | (2%) | (4%) | ||

## Cost of goods sold | 3.4 m | 2.9 m | 3.2 m | 2.7 m | |

## Gross profit | 3.7 m | 2 m | 1.7 m | 1.9 m | |

| 52% | 41% | 34% | 42% | |

## Sales and marketing expense | 9 m | 6.4 m | 2.7 m | 3.6 m | 3.6 m |

## R&D expense | 17.1 m | 15.1 m | 19 m | 16.2 m | 11.7 m |

## General and administrative expense | 16 m | 16 m | 9.8 m | 8.6 m | 7.6 m |

## Operating expense total | 42.1 m | 37.5 m | 31.4 m | 28.4 m | 24.6 m |

## Depreciation and amortization | 1.2 m | ||||

## EBIT | (30.7 m) | (32.4 m) | (15.3 m) | (19.7 m) | (20.7 m) |

| (431%) | (655%) | (316%) | (423%) | |

## Interest expense | 3.4 m | 4.4 m | 3.4 m | 2.6 m | 2 m |

## Interest income | 4 k | 6 k | 9 k | 19 k | 33 k |

## Net Income | (26.2 m) | (37.4 m) | (18.7 m) | (22 m) | (22.7 m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Cash | 15.5 m | 14.6 m | 14.3 m | 12.6 m | 9.6 m |

## Accounts Receivable | |||||

## Inventories | 3.7 m | 3.2 m | |||

## Current Assets | 24.6 m | 21.7 m | 21.2 m | 18.7 m | 14.9 m |

## PP&E | 1.1 m | 1.6 m | 1.6 m | 1.2 m | 3.1 m |

## Goodwill | 3.9 m | 3.9 m | 3.9 m | 3.9 m | 3.9 m |

## Total Assets | 42.1 m | 38.7 m | 37.7 m | 34.6 m | 31.6 m |

## Accounts Payable | 6.1 m | 5.5 m | 6.7 m | 5.9 m | 4.8 m |

## Short-term debt | |||||

## Current Liabilities | 14.9 m | 15.9 m | 8.4 m | 12.5 m | 18.4 m |

## Long-term debt | |||||

## Total Liabilities | 23.6 m | 18.6 m | |||

## Additional Paid-in Capital | 303.7 m | 331.8 m | 368 m | 388.8 m | 413.3 m |

## Retained Earnings | (300.9 m) | (338.3 m) | (357 m) | (379.1 m) | (401.7 m) |

## Total Equity | 3.1 m | 11 m | 13 m | ||

## Financial Leverage | 13.4 x | 3.2 x | 2.4 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Net Income | (26.2 m) | (37.4 m) | (18.7 m) | (22 m) | (22.7 m) |

## Depreciation and Amortization | 1.6 m | 779 k | 1.1 m | 1.2 m | 2.2 m |

## Accounts Receivable | (1.2 m) | 2.1 m | 328 k | (179 k) | 1.1 m |

## Inventories | (459 k) | (815 k) | 490 k | 471 k | 251 k |

## Accounts Payable | (409 k) | (1.1 m) | 1 m | (673 k) | (1.8 m) |

## Cash From Operating Activities | (34.6 m) | (30.3 m) | (20.5 m) | (19.5 m) | (18.1 m) |

## Purchases of PP&E | (519 k) | (764 k) | (611 k) | (67 k) | |

## Cash From Investing Activities | 3.7 m | (1.3 m) | (613 k) | 64 k | (1.7 m) |

## Dividends Paid | (75 k) | ||||

## Cash From Financing Activities | 20.8 m | 30.9 m | 20.8 m | 17.6 m | 16.8 m |

## Interest Paid | 2.3 m | 2.6 m | 2 m | 1.6 m | 1.4 m |

USD | Y, 2018 |
---|---|

## Financial Leverage | 3.1 x |

Report incorrect company information